Parameter
| Biomarker | Lipid metabolites (SM/PC/Cer) | Full name | Sphingomyelin / Phosphatidylcholine / Ceramide | Molecular Type | Metabolites (sphingomyelin, phosphatidylcholine, ceramide) |
|---|---|---|---|---|---|
| Molecular Formula | Diagnosis, differential diagnosis | Molecular Weight | Core Functional Dimensions | ||
| Disease | Cholangiocarcinoma (CCA) | Disease Subtypes | / | ||
| Organ | Bile duct/Liver | Test Sample / Technology Platform | Serum (liquid chromatography - mass spectrometry) | ||
| Pathobiological Mechanisms | Lipid metabolic abnormalities, tumor cells were tumor metabolic phenotype | ||||
| Clinical Availability Status | Study validation; Identify iCCA and HCC effectiveness is good | ||||
| Notes and Dynamics | 43:2 (SM), PC (O - 16-0 / plot) composed of panel, identify iCCA and HCC AUC > 0.90, is better than that of CA19-9 and AFP | ||||